Zealand Pharma company profile
Company profile
Zealand Pharma has 605 employees and is headquartered in Søborg, Denmark.
Patients with gastrointestinal and metabolic conditions, as well as those with other specialty diseases where treatment options remain limited, are the people the company's medicines are designed for. Zealand Pharma works across Denmark and the US, where it researches, develops and commercializes medicines built on peptides. Its product Zegalogue, a single-dose device for severe low blood sugar, sits alongside dasiglucagon-based systems for artificial pancreas use that combine insulin and dasiglucagon. The pipeline includes dasiglucagon for congenital hyperinsulinism and glepaglutide, a long-acting GLP-2 analog in Phase III trials for short bowel syndrome.
In the fiscal year ended December 2025, the company reported revenue of DKK 9.2 billion and net income of DKK 6.5 billion. It employed 605 people and is headquartered in Søborg, Denmark, where it was incorporated in 1997.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Denmark
- Headquarters
- Sydmarken 11, 2860, Søborg
- Employees
- 605
- Chief executive
- Adam Steensberg
- Founded
- 1997
- Fiscal year
- January - December
- Listing
- ZEAL · Nasdaq Copenhagen
- Currency
- DKK
- ISIN
- DK0060257814
- Website
- zealandpharma.com
Zealand Pharma and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Zealand PharmaZEAL | Denmark | $2.05B | 605 | 59.0% | 4.76 |
| Lakefront BiotherapeuticsLKFT | Netherlands | $2.19B | 196 | 57.5% | 2.53 |
| BioArcticBIOA.B | Sweden | $2.66B | 150 | 19.6% | 259.5 |
| Bavarian NordicBAVA | Denmark | $2.72B | 1,923 | 18.1% | 12.7 |
| CamurusCAMX | Sweden | $4.32B | 323 | 37.4% | 58.7 |
| IdorsiaIDIA | Switzerland | $1.26B | 424 | -68.4% | — |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
